Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations

NCT03220035 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03220035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03220035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
November 8, 2017
Completion date
December 31, 2024
Enrollment
4 (actual)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, ann arbor stage iii childhood non-hodgkin lymphoma, ann arbor stage iv childhood non-hodgkin lymphoma, ependymoma, ewing sarcoma, hepatoblastoma, langerhans cell histiocytosis, malignant germ cell tumor, malignant glioma, osteosarcoma, peripheral primitive neuroectodermal tumor, recurrent childhood central nervous system neoplasm, recurrent childhood non-hodgkin lymphoma, recurrent malignant solid neoplasm, recurrent neuroblastoma, refractory malignant solid neoplasm, refractory neuroblastoma, refractory non-hodgkin lymphoma, refractory primary central nervous system neoplasm, rhabdoid tumor, rhabdomyosarcoma, soft tissue sarcoma, wilms tumor